- Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection.
- A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting.
- As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised to offer technology solutions as a leading player in the neurological diagnostics space.
As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting, and the market for Brain Scientific’s (OTCQB: BRSF) innovative products appears to expand. A recent article published in Medical News Today discusses findings of the observational study examining neurological issues in patients hospitalized with COVID-19. The research which appeared in the journal JAMA Network Open unveils that the most prevalent neurological symptom observed in the clinical setting was acute encephalopathy also finding a relationship between neurological issues and a higher risk of dying in the hospital in patients infected with the SARS-CoV-2 virus (https://ibn.fm/j0F22).
Although COVID-19 is considered a respiratory disease that mainly affects patients’ pulmonary systems, research is increasingly documenting that the disease can affect many other organs and systems, including the brain. Since the start of the pandemic, it has been observed in a clinical setting that…
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
